October 18-20 | Tucson, AZ

The Research Institution GAP Fund and Accelerator Program Summit

AstraZeneca signs huge deal with UK start-up

Get our GAP Insights Newsletter

Join Upcoming Events

October 18-20, 2023 / Tucson, AZ
The annual summit for research institution gap fund and accelerator programs, including proof of concept programs, startup accelerators, and university venture funds

The Story

Pharma giant AstraZeneca has signed a huge deal with a UK start-up to create treatments for diabetes and other autoimmune diseases.

The FTSE 100 firm will team up with London-based Quell Therapeutics to collaborate on research and the licensing of any new medicines.

The aim is to develop treatments for Type 1 diabetes and inflammatory bowel disease through the use of genetically engineered ‘regulatory T-cells’ – ‘Tregs’ for short.

 

Full story: AstraZeneca in deal with start-up to fight diabetes | This is Money

Get the Report

More GAP News